Avelumab (anti-PD-L1)

Human IgG1 lambda1

Avelumab has a significant ADCC effect on HEK293/PD-L1 cells in a dose-dependent manner.The EC₅₀ for this effect is 12.64 and 13.49 ng/mL.

Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]

Customer Validation
Regardless of whether it was PANC-1 or PAN02 cells, the PD-L1-targeting effect of NGHP was comparable to that of the αPD-L1 (Avelumab, 1 μg/mL, 1 h), with the PD-L1 expression distribution exhibiting a rightward shift.

Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]

Customer Validation
Due to the relatively low PD-L1 expression on conventional PANC-1 cells, less avelumab was bound, leading to moderate toxicity of about 7.5% cell lysis rate for simple antibody and NGHP. While in PANC-1 cells with PD-L1 up-regulation induced by radiation, the ADCC-induced cell lysis rate increased.

Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]

Customer Validation
Schematic of RT (6 Gy at day 1 and day 3), PFD (10 mg/kg), HAase (6.5 mg/kg), and αPD-L1 (avelumab; 12 mg/kg) were used via intravenous (iv) injection from day 1 to day 9 (qod) in PAN02 cells/mPSCs bearing mice. Represent images of excised tumors after different treatments.

Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Biomater Res. 2026 Mar 4:30:0335. [Abstract]

Customer Validation
Schematic of RT (6 Gy at day 1 and day 3), PFD (10 mg/kg), HAase (6.5 mg/kg), and αPD-L1 (avelumab; 12 mg/kg) were used via intravenous (iv) injection from day 1 to day 9 (qod) in PAN02 cells/mPSCs bearing mice. Immunohistochemistry evaluation for α-SMA of PAN02&mPSC tumors obtained from C57BL/6 mice.

Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 Jul 15;6(7):102195. [Abstract]

Customer Validation
To demonstrate that MICA/B CAR⁺hnCD16⁺ iT cells are capable of flexibly utilizing antibodies to supplement CAR efficacy, MICA/B CAR⁺hnCD16⁺ iT cells were co-cultured with the MICA/B^HighEGFR⁺PDL1⁺HER2⁺ CaSki tumor cell line and individually supplemented with different therapeutic antibodies: Cetuximab targeting EGFR, Avelumab against PDL1, and Herceptin for HER2.

Avelumab (anti-PD-L1) purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Mar 15;8(1):107. [Abstract]

Customer Validation
Co-culture of A2058 cells transfected with control or SIRT7 overexpression plasmid with TG treatment and activated T cells (1:3) for 24 h with or without the treatment with PD-L1 neutralizing antibody (Avelumab, 20 μg/mL) for 8 h. Cytotoxicity was then quantified by a spectrometer at OD (570 nm) followed by crystal violet staining.